Clinical trial

Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer

NCT01288261

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2011-01-01

PhasePHASE1

Study timeline

Study start (unknown)2011-01-01Date precision: month

Registry last updated2016-04-21

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Human Epidermal Growth Factor 2 Negative Carcinoma of Breastunresolved

Male Breast Cancerunresolved

Recurrent Breast Cancerunresolved

Stage IIIC Breast Cancerunresolved

Stage IV Breast Cancerunresolved

Interventions

paclitaxelDRUG · verified · RxNorm: paclitaxel

bavituximabBIOLOGICAL

laboratory biomarker analysisOTHER

pharmacological studyOTHER

Sponsors & collaborators

University of Arizonalead sponsor

National Cancer Institute (NCI)collaborator

Mapped research locations

TucsonArizona, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01288261 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.